Neogenomics Inc (NEO) financials
Neogenomics revenue and earnings by year
Neogenomics's revenue was $727 million in the fiscal year to December 31, 2025, up 10.1% from the year before. Net income was -$108 million, -14.9% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 13.5% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 727 | 661 | 592 | 510 | 484 | 444 | 409 | 277 | 240 | 232 |
| Revenue growth | 10.1% | 11.6% | 16.1% | 5.2% | 9.0% | 8.7% | 47.7% | 15.2% | 3.6% | — |
| Gross profit | 314 | 290 | 245 | 188 | 187 | 186 | 197 | 127 | 102 | 98 |
| Gross margin | 43.2% | 43.9% | 41.3% | 36.9% | 38.6% | 41.8% | 48.1% | 46.0% | 42.4% | 42.3% |
| Operating income | -116 | -92 | -108 | -158 | -119 | -14 | 13 | 10 | 4 | 2 |
| Operating margin | -15.9% | -13.9% | -18.2% | -30.9% | -24.5% | -3.1% | 3.2% | 3.6% | 1.6% | 0.9% |
| Net income | -108 | -79 | -88 | -144 | -8 | 4 | 8 | 3 | -0 | -6 |
| Net margin | -14.9% | -11.9% | -14.9% | -28.3% | -1.7% | 0.9% | 2.0% | 1.0% | -0.2% | -2.6% |
| Diluted EPS | -$0.83 | -$0.62 | -$0.70 | -$1.16 | — | $0.05 | $0.07 | $0.07 | -$0.15 | -$0.40 |
| Free cash flow | -22 | -34 | -31 | -97 | -91 | -28 | 3 | 30 | 4 | 14 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open NEO in Markets.
How Neogenomics makes money
Revenue by segment in the quarter to September 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Client Direct Billing | $136M | 64.8% |
| Commercial Insurance | $44.7M | 21.3% |
| Medicare & Other Governmental | $29.0M | 13.9% |
See also: NEO returns
No forecast, no recommendation. This page describes Neogenomics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.